81
59
Growth Score
-4 pts
Heat Score
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
577960
Oregon Therapeutics is a developer of new anti-cancer drugs.
About the Company
Oregon Therapeutics is developing XCE853 : disruptive targeted therapy “first in class” and “best in class” in oncology. XCE853 is based on an innovative and unique mechanism of action: inhibition of protein disulfide isomerase. OregonTherapeutics first objective is to bring XCE853 into the clinical phase for the treatment of cancer within 2 years.
Based on the scientific rationale to exploit the metabolic vulnerability of some cancers, the two priority indications are ovarian cancer and advanced pancreatic cancer.
